Testing upadacitinib for stable vitiligo
Treatments studied
Part of Skin clinical trials.
This trial tests a daily pill (upadacitinib) to see if it can improve vitiligo after an initial treatment (NECS). It is for people whose vitiligo is stable and covers a limited area.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old
- You have non-segmented vitiligo (white patches on both sides of your body) and it has been stable for at least a year
- Your vitiligo covers no more than 30% of your body
- You have not used certain treatments (like laser, phototherapy, or specific oral medications) for vitiligo within the last month
- You have no active infections, hepatitis, HIV, or tuberculosis, and your liver and kidneys are working well
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called TEV-53408 to see if it can help with vitiligo, a condition that causes white patches on the skin. It may help by restoring skin color, and the study will check how safe and effective it is.
This trial tests whether adding a type of light therapy (narrow-band UVB) to a daily pill called ritlecitinib works better than the pill alone for treating vitiligo. It may help if you have non-segmental vitiligo covering a moderate amount of skin.
This trial tests whether taking short courses of steroid pills alongside a skin cell transplant procedure helps treat stubborn vitiligo patches on the elbows and knees that have not improved with standard treatments.
This study tests an experimental medication (ACT-777991) taken by mouth to see if it can help repigment skin in adults with non-segmental vitiligo. It aims to learn how safe it is and how well it works.
This study tests an investigational pill called povorcitinib phosphate to see if it can help repigment skin in adults with nonsegmental vitiligo. It is a phase 3 trial in China, and participants will stop other vitiligo treatments during the study.
This trial tests an oral medication called zasocitinib to see if it can help repigment skin in adults with nonsegmental vitiligo. It may be an option for people whose vitiligo covers a moderate amount of their body and who have not had certain recent treatments.
Hear when a new Vitiligo trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.